ArticleAllergy2021
Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: Don't give up on the second dose!
Abstract readLetter
In one paragraph
Article in Allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Meta-analysis.JAMA internal medicine · 2022Pooled it
- Safety of COVID-19 revaccination in patients with prior hypersensitivity reactions: a retrospective study.Tropical diseases, travel medicine and vaccines · 2025Article
- Adverse reactions to mRNA COVID-19 vaccine in people with allergies in Japan.Global health & medicine · 2024Article
- Article
- Gastrointestinal reflux contributes to laryngopharyngeal symptoms that mimic anaphylaxis: COVID-19 vaccination experience.The journal of allergy and clinical immunology. Global · 2024Article
- Article
- Anaphylatoxin Complement 5a in Pfizer BNT162b2-Induced Immediate-Type Vaccine Hypersensitivity Reactions.Vaccines · 2023Article
- Vaccine confidence among those living with allergy during the COVID pandemic (ACCORD): A scoping review.The journal of allergy and clinical immunology. Global · 2023Article
- Article
- Allergy to Omalizumab: Lessons from a Reaction to the Coronavirus 2019 Vaccine.Internal medicine (Tokyo, Japan) · 2023Article
- Clinical Phenotypes of Immediate First-Dose Reactions to mRNA COVID-19: A Multicenter Latent Class Analysis.The journal of allergy and clinical immunology. In practice · 2023Article
- The conundrum of COVID-19 mRNA vaccine-induced anaphylaxis.The journal of allergy and clinical immunology. Global · 2023Review
- Skin Testing and Basophil Activation Testing Is Useful for Assessing Immediate Reactions to Polyethylene Glycol-Containing Vaccines.Vaccines · 2023Article
- Anaphylaxis induced by mRNA COVID-19 vaccines: follow-up and booster dose after previous desensitization.Frontiers in allergy · 2023Article
- Serum polyethylene glycol-specific IgE and IgG in patients with hypersensitivity to COVID-19 mRNA vaccines.Allergology international : official journal of the Japanese Society of Allergology · 2022Article
- Adverse Events and Safety of SARS-CoV-2 Vaccines: What's New and What's Next.The journal of allergy and clinical immunology. In practice · 2022Review
- Risk stratification through allergy history: single-centre experience of specialized COVID-19 vaccine clinic.Clinical and experimental immunology · 2022Article
- Rare Heterogeneous Adverse Events Associated with mRNA-Based COVID-19 Vaccines: A Systematic Review.Medicines (Basel, Switzerland) · 2022Review
- Allergic reactions to the coronavirus disease 2019 vaccine (ARCOV) study: The McGill University Health Centre experience.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Matthew S KrantzDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.ORCID 0000-0001-7589-9127
Maria A Bruusgaard-MouritsenDepartment of Dermatology and Allergy, Allergy Clinic, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark.ORCID 0000-0003-4259-5711
Grace KooDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.
Elizabeth J PhillipsDivision of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Cosby A StoneDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.ORCID 0000-0002-1888-4188
Lene H GarveyDepartment of Dermatology and Allergy, Allergy Clinic, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark.ORCID 0000-0002-7777-4501
Funding
Understanding and preventing HLA-associated drug reactionsP50GM115305 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RODEN, DAN M · 2015 to 2019
$13.0MGenetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivorsR01HG010863 · NHGRI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2019 to 2022
$3.1MLearning Health System Scholar Program at VanderbiltK12HS026395 · AHRQ · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ROTHMAN, RUSSELL L., ROUMIE, CHRISTIANNE L. · 2018 to 2022
$2.7MSingle Cell definition of pathogenic T cells in Drug-induced Stevens-Johnson-Syndrome/Toxic epidermal necrolysisR21AI139021 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2018 to 2019
$435kNATIENS: A Phase III Randomized Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisR34AI136815 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2018 to 2018
$205kAHRQ HHS 1K12HS026395-01AHRQ HHS K12 HS026395National Health and Medical Research Foundation of AustraliaNHGRI NIH HHS R01 HG010863NIAID NIH HHS R21 AI139021NIAID NIH HHS R34 AI136815NIGMS NIH HHS P50 GM115305NIH HHS 1P50GM115305-01NIH HHS 1 R01 HG010863-01NIH HHS R21AI139021NIH HHS R34AI136815
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnaphylaxisCOVID-19COVID-19 VaccinesHumansRNA, MessengerSARS-CoV-2COVID-19 VaccinesRNA, MessengeranaphylaxisSARS-CoVvaccines
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.